MedPath

Dexrazoxane

Generic Name
Dexrazoxane
Brand Names
Savene, Totect, Zinecard
Drug Type
Small Molecule
Chemical Formula
C11H16N4O4
CAS Number
24584-09-6
Unique Ingredient Identifier
048L81261F
Background

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]

The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

Indication

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.

Associated Conditions
Doxorubicin Induced Cardiomyopathy, Drug Extravasation
Clinical Trials
Related News

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Phase 1
Terminated
Conditions
Relapsed Acute Lymphoblastic Leukemia
Allergy to PEG e.Coli Asparaginase
Allergy to Native e.Coli Asparaginase
Interventions
Drug: Triple Intrathecal Therapy
First Posted Date
2009-06-25
Last Posted Date
2019-02-19
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
1
Registration Number
NCT00928200
Locations
🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Phase 1
Completed
Conditions
Sarcoma
Interventions
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Biological: filgrastim
First Posted Date
2008-08-28
Last Posted Date
2014-07-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
24
Registration Number
NCT00742924
Locations
🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States

🇺🇸

Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States

and more 85 locations

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Not Applicable
Terminated
Conditions
Osteosarcoma
Interventions
Behavioral: Questionnaire
Procedure: Surgery
First Posted Date
2008-05-07
Last Posted Date
2014-09-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
7
Registration Number
NCT00673179
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2007-10-30
Last Posted Date
2015-06-08
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
25
Registration Number
NCT00550901

Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Phase 2
Completed
Conditions
Anthracycline Extravasation
First Posted Date
2007-10-24
Last Posted Date
2015-10-21
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
23
Registration Number
NCT00548561
Locations
🇩🇰

Aalborg Hospital South, Aalborg, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Herlev County Hospital, Herlev, Denmark

and more 6 locations

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Phase 2
Completed
Conditions
Extravasation
First Posted Date
2007-10-24
Last Posted Date
2015-10-21
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
57
Registration Number
NCT00548704
Locations
🇵🇱

Centre of Oncology - Krakow Division, Krakow, Poland

🇵🇱

Dolnoslaski Centrum Onkologii oddzial Chemoterapii, Wroclaw, Poland

🇩🇰

Aarhus County Hospital, Aarhus, Denmark

and more 30 locations

Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

Phase 2
Terminated
Conditions
Sarcoma
Interventions
Biological: filgrastim
Genetic: protein expression analysis
Other: immunoenzyme technique
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy
First Posted Date
2007-10-16
Last Posted Date
2014-08-28
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
7
Registration Number
NCT00544778

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

First Posted Date
2006-12-13
Last Posted Date
2013-03-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
51
Registration Number
NCT00410488
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Acute Lymphoblastic Leukemia in Children

First Posted Date
2006-11-17
Last Posted Date
2024-11-27
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
800
Registration Number
NCT00400946
Locations
🇨🇦

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇺🇸

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

🇨🇦

Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada

and more 5 locations

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

First Posted Date
2006-06-08
Last Posted Date
2013-06-28
Lead Sponsor
Children's Oncology Group
Registration Number
NCT00334867
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy